Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company’s manufacturing facility in Bolognana, Italy, to produce RYPLAZIM(r).
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
